Regulatory Roundup: FDA Publishes CDER Presentation, and more. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Publishes CDER Presentation, and more.

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has published on its website a presentation given by Center for Drug Evaluation and Research (CDER) Director Janet Woodcock on Dec. 9. 2010. The presentation provides a thorough overview of CDER efforts, including the Sentinel initiative, new molecular entity approvals, REMS, and more.

FDA issued on Jan. 7, 2011 another warning about criminals posing as agency officials and other law enforcement personnel as part of a continued international extortion scam. In most cases, criminals call victims who have purchased drugs over the Internet and say they are being charged a fine of $100 to $250,000. Victims are asked to wire the money, and if they do not do so, are often threatened. See the agency’s list of questions and answers about the scam.

The agency has announced a CDER Forum for International Drug Regulatory Authorities to take place April 4–8, 2011, in College Park, MD. The annual forums provide an overview of CDER offices. The 2011 forum will also focus on a product review case study of Etravirine, which is used to treat HIV, to demonstrate how CDER product reviews work. Registration information and requests should be sent to CDERForum@fda.hhs.gov.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here